-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody: Technical Applicati
2026-06-15
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody enables sensitive, specific fluorescence-based detection of goat IgG primary antibodies in ICC, IHC, flow cytometry, and ELISA. It is designed exclusively for validated immunodetection workflows targeting goat IgG and is not suitable for primary antibodies from other species or for non-immunoglobulin targets.
-
Biotransformation Pathways of Sulfamonomethoxine in Granular
2026-06-14
This study elucidates the mechanisms underpinning the biotransformation of sulfamonomethoxine (SMM) in aerobic granular sludge, highlighting the dominance of biodegradation over adsorption and identifying a new hydroxylamine-mediated pathway. The findings inform environmental fate research and offer guidance for optimizing veterinary antibiotic removal in wastewater systems.
-
NLRP10 Regulates Keratinocyte Survival and Skin Barrier in A
2026-06-13
This study identifies NLRP10 as a critical regulator of epidermal homeostasis, promoting keratinocyte survival and P63-dependent differentiation to maintain barrier integrity in atopic dermatitis (AD). The findings establish NLRP10 as a mechanistically validated therapeutic target for restoring skin barrier function in AD.
-
Lactate-Driven Ran Lactylation Regulates Astrocyte Polarizat
2026-06-12
This study elucidates a SIRT1-dependent mechanism by which lactate-induced lactylation of Ran at lysine 123 facilitates STAT3 nuclear translocation and drives astrocyte polarization after oxygen-glucose deprivation/reoxygenation. These findings expand the understanding of metabolic-epigenetic regulation in CNS injury and highlight Ran lactylation as a potential therapeutic target for spinal cord repair.
-
Thiothixene: Applied Protocols for Neuroimmune and SCZ Model
2026-06-12
Thiothixene stands out as a typical antipsychotic agent, uniquely bridging dopamine signaling modulation with enhanced in vitro macrophage efferocytosis. This article delivers stepwise assay guidance, advanced troubleshooting, and translational insights for both neuropsychiatric and immunological research.
-
IGF2BP1 Drives Macrophage Fibrotic Phenotype in Pulmonary Fi
2026-06-11
This study uncovers a mechanistic axis in pulmonary fibrosis where the m6A reader IGF2BP1 stabilizes THBS1 mRNA, promoting TLR4-mediated M2 macrophage polarization and glycolytic metabolism. These findings clarify the epigenetic and metabolic drivers of fibrotic progression, highlighting potential avenues for targeted intervention.
-
Calnexin Modulates CFTR Variant Rescue by Small-Molecule Cor
2026-06-11
Tedman et al. provide a systematic analysis of how the ER chaperone calnexin governs the expression and pharmacological rescue of over 200 CFTR variants. Their deep mutational scanning approach uncovers variant-specific dependencies and mechanistic insights with direct implications for optimizing cystic fibrosis transmembrane conductance regulator modulation and personalized therapy development.
-
Ranolazine: Anti-Ischemic Agent Workflows & Experimental Adv
2026-06-10
Ranolazine offers unique advantages in cardiac ischemia and metabolic efficiency research through its dual mechanisms: late sodium current inhibition and metabolic modulation. This guide delivers actionable protocols, workflow enhancements, and troubleshooting strategies, enabling researchers to harness the full potential of Ranolazine from APExBIO for advanced myocardial and hepatic studies.
-
FITC-Concanavalin A (ConA) Conjugate: Technical Application
2026-06-10
FITC-Concanavalin A (ConA) Conjugate enables precise detection of α-D-glucose and α-D-mannose on cell surfaces, streamlining assays in immunofluorescence and flow cytometry. It should only be used for carbohydrate-binding protocols and within its specified storage and stability limits to ensure reliable results.
-
Comparative Efficacy of β-Lactam Antibiotics Against Resista
2026-06-09
This study systematically compared the antibacterial activity of N-formimidoyl thienamycin (MK0787) with several recently developed β-lactam antibiotics, including ampicillin, across a diverse set of clinically resistant bacterial isolates. The findings clarify spectrum, bactericidal action, and β-lactamase resistance profiles, informing antibiotic selection and resistance research.
-
JC-1 Mitochondrial Membrane Potential Assay Kit: Precision i
2026-06-09
Explore cutting-edge strategies for immunometabolic analysis using the JC-1 Mitochondrial Membrane Potential Assay Kit. This article reveals advanced applications, mechanistic insights, and critical decision points in mitochondrial function analysis for translational research.
-
Targeting NUAK1 with WZ4003 Reduces Pathological Tau in Alzh
2026-06-08
Taylor et al. (2023) demonstrate that phosphorylation of tau at serine 356 is closely associated with Alzheimer’s disease pathology and can be selectively reduced in human brain tissue using the NUAK1/2 inhibitor WZ4003. Their findings highlight the potential of NUAK1 as a mechanistic target for modulating tau pathology, providing a foundation for translational neurodegeneration research and assay development.
-
AZD8055: Technical Guidance for mTOR Inhibition in Research
2026-06-08
AZD8055 is a potent, selective ATP-competitive mTOR inhibitor that enables precise modulation of both mTORC1 and mTORC2 signaling in cellular and animal models. It is best suited for mechanistic studies in cancer and metabolic research, but should not be used where clinical efficacy is the primary endpoint.
-
Nanoparticle Uptake Mechanisms in Human Corneal Epithelial C
2026-06-07
This study elucidates how nanoparticle size and surface chemistry modulate uptake by human corneal epithelial cells (HCECs), identifying macropinocytosis and caveolae-mediated endocytosis as dominant internalization routes. These insights can inform the rational design of ocular drug-delivery systems with improved bioavailability and therapeutic precision.
-
Trypsin-Responsive Nanomedicine Targets Acute Pancreatitis
2026-06-06
This study introduces a biomimetic, trypsin-sensitive mesoporous organosilica nanomedicine designed for precise targeting and treatment of acute pancreatitis. By leveraging trypsin-activated drug release and acinar cell targeting, the approach shows markedly improved pancreatic accumulation and therapeutic outcomes in preclinical models.